SCO-101 has previously been studied together with chemotherapy in patients with colorectal cancer, where the compound counteracts resistance to irinotecan by inhibiting the drug efflux pump ABCG2 and the metabolic liver enzyme UGT1A1 [8]. The gene discussed is ABCG2; the disease is colorectal cancer.